This episode of The Deep Dive explores contemporary challenges in neuropsychiatry, specifically focusing on the overdiagnosis of ADHD and the rise of stimulant prescriptions. Expert interviews with Dr. C. Thomas Gualtieri trace the historical evolution of ADHD, arguing that many modern patients may actually be experiencing anxiety, work overload, or natural personality traits rather than a true neurodevelopmental disorder. Beyond ADHD, the report examines novel drug combinations for treating alcohol use disorder, bipolar depression, and obstructive sleep apnea. It also provides practical guidance on using affordable generic alternatives for expensive branded medications like Auvelity and Lybalvi. Furthermore, research updates review the efficacy of GLP-1 agonists for addiction and the use of long-acting injectables for maintaining stability in bipolar disorder. Ultimately, the source serves as a clinical guide for balancing innovative pharmacological treatments with cautious, evidence-based diagnostic practices.

This episode of The Deep Dive reviews the Carlat Publishing Addiction Treatment Report and provides clinical guidance on managing substance use disorders within acute care and inpatient settings. Expert interviews highlight the shift toward using phenobarbital and front-loaded diazepam for alcohol withdrawal, emphasizing these methods over traditional symptom-triggered protocols to improve efficiency and safety. The publication also outlines rapid buprenorphine induction strategies, such as high-dose sublingual administration and long-acting injections, to treat opioid use disorder during brief hospital stays. Additional articles offer evidence-based approaches for treating patients with comorbid bipolar disorder and assessing new research on vaping cessation and methadone effectiveness. Collectively, these sources advocate for proactive pharmacological interventions to stabilize patients during critical windows of medical contact.

This episode is a deep dive from The Carlat Addiction Treatment Report. It examines various evidence-based strategies for managing substance use disorders, specifically comparing pharmacological and psychotherapeutic interventions. It features an in-depth look at motivational interviewing, highlighting how collaborative dialogue and the resolution of ambivalence can drive a patient's commitment to recovery. Another focal point is 12-step facilitation, a clinical framework designed to bridge the gap between professional therapy and community-based support groups. The sources also introduce Brixadi, a flexible, long-acting injectable buprenorphine, as a modern tool for treating opioid use disorder in both outpatient and acute care settings. Ultimately, the material serves as a clinical guide to tailoring addiction treatment based on the specific substance involved and the unique needs of the individual.